{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:20:18Z","timestamp":1783088418049,"version":"3.54.6"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004635","name":"Fru Berta Kamprads Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004635","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.radonc.2025.111323","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:43:42Z","timestamp":1765471422000},"page":"111323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Routinely collected health data on 10-year genitourinary and gastrointestinal morbidity after ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer in the randomised, non-inferiority, phase 3 trial HYPO-RT-PC"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5205-8773","authenticated-orcid":false,"given":"Astrid E.","family":"Persson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Kjell\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Garmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8837-4696","authenticated-orcid":false,"given":"Gabriel","family":"Adrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Stattin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Widmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7983-9778","authenticated-orcid":false,"given":"Per","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1354-8537","authenticated-orcid":false,"given":"Adalsteinn","family":"Gunnlaugsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111323_b0005","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.111323_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2005.06.009","article-title":"The \u03b1\/\u03b2 ratio for prostate cancer: what is it, really?","volume":"76","author":"Bentzen","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111323_b0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13014-014-0275-6","article-title":"Hypofractionated radiotherapy for prostate cancer","volume":"9","author":"Hegemann","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111323_b0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.111323_b0025","doi-asserted-by":"crossref","first-page":"S4414","DOI":"10.1016\/S0167-8140(25)04191-X","article-title":"4981 Ultra-hypofractionated radiotherapy for localised prostate cancer: 10-year outcomes of the HYPO-RT-PC phase 3 trial (ISRCTN45905321)","volume":"206","author":"Nilsson","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111323_b0030","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.111323_b0035","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2013.53.8652","article-title":"Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity","volume":"32","author":"Yu","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111323_b0040","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/cncr.30101","article-title":"Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer","volume":"122","author":"Halpern","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.111323_b0045","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1200\/JCO.2017.75.5371","article-title":"Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer","volume":"36","author":"Pan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111323_b0050","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.prro.2020.02.014","article-title":"Costs and complications after a diagnosis of prostate cancer treated with time-efficient modalities: an analysis of national Medicare data","volume":"10","author":"Tang","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111323_b0055","doi-asserted-by":"crossref","first-page":"e2809","DOI":"10.1136\/bmj.e2809","article-title":"Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review","volume":"344","author":"Akl","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2025.111323_b0060","doi-asserted-by":"crossref","first-page":"e1119","DOI":"10.1136\/bmj.e1119","article-title":"Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors","volume":"344","author":"Hr\u00f3bjartsson","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2025.111323_b0065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/ije\/dyv305","article-title":"Cohort Profile Update: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base\u2014a refined prostate cancer trajectory","volume":"45","author":"Van Hemelrijck","year":"2015","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.radonc.2025.111323_b0070","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2340\/sju.v59.42272","article-title":"How to improve cancer care by use of guidelines and quality registers","volume":"59","author":"Stattin","year":"2024","journal-title":"Scand J Urol"},{"key":"10.1016\/j.radonc.2025.111323_b0075","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2340\/sju.v59.42656","article-title":"2023\/2024 update of the national prostate cancer guidelines in Sweden","volume":"59","author":"Stranne","year":"2024","journal-title":"Scand J Urol"},{"key":"10.1016\/j.radonc.2025.111323_b0080","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"10.1016\/j.radonc.2025.111323_b0085","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bcpt.12613","article-title":"The first decade with the Swedish Prescribed Drug Register \u2013 a systematic review of the output in the scientific literature","volume":"119","author":"Wallerstedt","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.radonc.2025.111323_b0090","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.radonc.2025.111323_b0095","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10654-019-00511-8","article-title":"The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research","volume":"34","author":"Ludvigsson","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.radonc.2025.111323_b0100","unstructured":"World Health Organization. Anatomical Therapeutic Chemical (ATC) Classification, https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification; 2023 [accessed 30 November 2023]."},{"key":"10.1016\/j.radonc.2025.111323_b0105","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/bjc.1995.364","article-title":"Review of survival analyses published in cancer journals","volume":"72","author":"Altman","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2025.111323_b0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/CLEP.S282475","article-title":"Adaptation of the Charlson comorbidity index for register-based research in Sweden","volume":"13","author":"Ludvigsson","year":"2021","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.radonc.2025.111323_b0115","article-title":"Visualizing time-varying effect in survival analysis: 5 complementary plots to Kaplan-Meier curve","volume":"2022","author":"Huang","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.radonc.2025.111323_b0120","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(24)00720-4","article-title":"The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials","volume":"26","author":"Nikitas","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111323_b0125","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/21681805.2016.1194460","article-title":"Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study","volume":"50","author":"Fridriksson","year":"2016","journal-title":"Scand J Urol"},{"key":"10.1016\/j.radonc.2025.111323_b0130","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1001\/jamaoncol.2024.4397","article-title":"Long-term adverse effects and complications after prostate cancer treatment","volume":"10","author":"Unger","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.111323_b0135","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(25)00205-0","article-title":"Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial","volume":"26","author":"Tree","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111323_b0140","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","article-title":"Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43\u2008895 trials and 5\u2008685\u2008738 individuals across 989 unique drugs and 286 conditions in England","volume":"3","author":"Tan","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.radonc.2025.111323_b0145","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jamaoncol.2023.4267","article-title":"Increasing use of shorter-course radiotherapy for prostate cancer","volume":"9","author":"Yu","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.111323_b0150","unstructured":"Cronford P, Tilki D, van den Bergh RCN, Eberli D, De Meerleer M, De Santis S, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: 6. Treatment, https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/treatment; 2025 [accessed 23 October 2025]."},{"key":"10.1016\/j.radonc.2025.111323_b0155","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer V.2.2026, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf; 2025 [accessed 23 October 2025]."},{"key":"10.1016\/j.radonc.2025.111323_b0160","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial","volume":"22","author":"Fransson","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111323_b0165","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ijrobp.2007.11.044","article-title":"Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer","volume":"70","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111323_b0170","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.ijrobp.2017.07.040","article-title":"National population-based study comparing treatment-related toxicity in men who received intensity modulated versus 3-dimensional conformal radical radiation therapy for prostate cancer","volume":"99","author":"Sujenthiran","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025053277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025053277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:29:14Z","timestamp":1773923354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025053277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":34,"alternative-id":["S0167814025053277"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111323","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Routinely collected health data on 10-year genitourinary and gastrointestinal morbidity after ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer in the randomised, non-inferiority, phase 3 trial HYPO-RT-PC","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111323","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111323"}}